BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advances Personalized Immunotherapy Technology Targeting Advanced Breast Cancer Patients
- Completed development of novel, frozen formulation of Bria-IMT for on-demand shipment to clinical sites
- New formulation to accommodate higher patient volumes at reduced per-dose costs
- Mechanism of action and proof of concept achieved in FDA-approved clinical trial with advanced breast cancer patients
- The global cancer immunotherapy market is expected to be valued at nearly $125 billion by the end of 2024
- Breast cancer remains one of the most commonly diagnosed cancers among women globally, with 2.1 million cases expected in 2018
Battling a cancer prognosis is often referred to as “fighting the good fight,” but it’s a tough, uphill battle for many patients combating advanced breast cancer. The need for effective, lasting breast cancer treatment is urgent, the Cancer Research Institute (http://nnw.fm/jV3li) states in an article titled ‘How is Immunotherapy Changing the Outlook for Patients with Breast Cancer’. As an immuno-oncology focused biotechnology company, BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is dedicated to developing the first off-the-shelf, personalized immunotherapy targeting the unmet needs of advanced breast cancer patients.
BriaCell’s lead cancer drug candidate – Bria-IMT – has shown promise in FDA-approved clinical trials, suggesting excellent safety and efficacy in patients who matched the Bria-IMT HLA types. Bria-IMT activates the immune system to destroy cancer cells in a way that’s believed to be both unique and more effective than other, similar approaches. BriaCell recently announced the imminent clinical use of a novel frozen formulation of Bria-IMT for on-demand shipment to clinical sites to accommodate higher patient volumes at reduced per-dose costs (http://nnw.fm/160Iu). Bria-IMT is currently being tested in a phase I/IIa clinical trial with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)], listed on ClinicalTrials.gov as NCT03328026.
“Currently, the old formulation of Bria-IMT used in the clinical trials was cumbersome to prepare, as it had to be processed the day before administration to patients. This created a great deal of inconvenience and complexities for the manufacturer, clinicians and patients,” Dr. Bill Williams, BriaCell’s president and CEO, stated in a news release (http://nnw.fm/iHq8m). “The new frozen formulation has shown improved potency and stability in vitro and, based on its constituents and injection route, is expected to be highly bioavailable. This enhances Bria-IMT’s potential to address patient needs as a ready-to-use treatment alternative that can be prepared in advance, is easily transportable to distant locations in large quantities, is easy to use, and is safe and highly effective.”
The global cancer immunotherapy market is expected to jump from $37.5 billion in 2015 to $124.9 billion by the end of 2024, maintaining a compound annual growth rate of 14.6 percent during the forecast period from 2016 to 2024, according to Transparency Market Research (http://nnw.fm/6aJap). The global cancer immunotherapy market is expected to witness a spike in demand for immune checkpoint inhibitors due to their high success rates and improved overall efficiency, the report states. Globally, more than two million new breast cancer cases were estimated to have been diagnosed during 2018.
BriaCell is on the cutting edge of cancer treatment with its proprietary, effective and safe immunotherapy applications, Williams explained during a featured interview on Uptick Newswire’s Stock Day Podcast. Williams shared his enthusiasm for the company’s technological advancements in battling advanced breast cancer as he reviewed progress made and plans for the company’s future (http://nnw.fm/PoA5U).
“We’ve dosed over 20 patients now with Bria-IMT. It has been very safe and well tolerated,” Williams said in the interview. “We’ve seen this strong anti-tumor response in the patients who match Bria-IMT at HLA alleles, so we are very excited about the prospects of these findings.”
BriaCell recently presented a poster at a 2019 Keystone Symposia scientific conference, held January 20-24 at the Fairmont Hotel in Vancouver, British Columbia. The presentation highlighted BriaCell’s recent clinical and research-focused development of Bria-IMT and BriaDX programs (http://nnw.fm/8shGc). BriaDX is the corresponding companion diagnostic test that helps identify those patients most likely to benefit from treatment with Bria-IMT and Bria-OTS, BriaCell’s off-the-shelf personalized immunotherapy, which is currently under development with plans to enter the clinic in 2H2019.
BriaCell management also attended Biotech Showcase 2019, an important investor conference that took place January 7-9 at the Hilton Union Square in San Francisco, California.
For more information, visit the company’s website at www.BriaCell.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Completed development of novel, frozen formulation of Bria-IMT for on-demand shipment to clinical sites
- New formulation to accommodate higher patient volumes at reduced per-dose costs
- Mechanism of action and proof of concept achieved in FDA-approved clinical trial with advanced breast cancer patients
- The global cancer immunotherapy market is expected to be valued at nearly $125 billion by the end of 2024
- Breast cancer remains one of the most commonly diagnosed cancers among women globally, with 2.1 million cases expected in 2018
Battling a cancer prognosis is often referred to as “fighting the good fight,” but it’s a tough, uphill battle for many patients combating advanced breast cancer. The need for effective, lasting breast cancer treatment is urgent, the Cancer Research Institute (http://nnw.fm/jV3li) states in an article titled ‘How is Immunotherapy Changing the Outlook for Patients with Breast Cancer’. As an immuno-oncology focused biotechnology company, BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is dedicated to developing the first off-the-shelf, personalized immunotherapy targeting the unmet needs of advanced breast cancer patients.
BriaCell’s lead cancer drug candidate – Bria-IMT – has shown promise in FDA-approved clinical trials, suggesting excellent safety and efficacy in patients who matched the Bria-IMT HLA types. Bria-IMT activates the immune system to destroy cancer cells in a way that’s believed to be both unique and more effective than other, similar approaches. BriaCell recently announced the imminent clinical use of a novel frozen formulation of Bria-IMT for on-demand shipment to clinical sites to accommodate higher patient volumes at reduced per-dose costs (http://nnw.fm/160Iu). Bria-IMT is currently being tested in a phase I/IIa clinical trial with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)], listed on ClinicalTrials.gov as NCT03328026.
“Currently, the old formulation of Bria-IMT used in the clinical trials was cumbersome to prepare, as it had to be processed the day before administration to patients. This created a great deal of inconvenience and complexities for the manufacturer, clinicians and patients,” Dr. Bill Williams, BriaCell’s president and CEO, stated in a news release (http://nnw.fm/iHq8m). “The new frozen formulation has shown improved potency and stability in vitro and, based on its constituents and injection route, is expected to be highly bioavailable. This enhances Bria-IMT’s potential to address patient needs as a ready-to-use treatment alternative that can be prepared in advance, is easily transportable to distant locations in large quantities, is easy to use, and is safe and highly effective.”
The global cancer immunotherapy market is expected to jump from $37.5 billion in 2015 to $124.9 billion by the end of 2024, maintaining a compound annual growth rate of 14.6 percent during the forecast period from 2016 to 2024, according to Transparency Market Research (http://nnw.fm/6aJap). The global cancer immunotherapy market is expected to witness a spike in demand for immune checkpoint inhibitors due to their high success rates and improved overall efficiency, the report states. Globally, more than two million new breast cancer cases were estimated to have been diagnosed during 2018.
BriaCell is on the cutting edge of cancer treatment with its proprietary, effective and safe immunotherapy applications, Williams explained during a featured interview on Uptick Newswire’s Stock Day Podcast. Williams shared his enthusiasm for the company’s technological advancements in battling advanced breast cancer as he reviewed progress made and plans for the company’s future (http://nnw.fm/PoA5U).
“We’ve dosed over 20 patients now with Bria-IMT. It has been very safe and well tolerated,” Williams said in the interview. “We’ve seen this strong anti-tumor response in the patients who match Bria-IMT at HLA alleles, so we are very excited about the prospects of these findings.”
BriaCell recently presented a poster at a 2019 Keystone Symposia scientific conference, held January 20-24 at the Fairmont Hotel in Vancouver, British Columbia. The presentation highlighted BriaCell’s recent clinical and research-focused development of Bria-IMT and BriaDX programs (http://nnw.fm/8shGc). BriaDX is the corresponding companion diagnostic test that helps identify those patients most likely to benefit from treatment with Bria-IMT and Bria-OTS, BriaCell’s off-the-shelf personalized immunotherapy, which is currently under development with plans to enter the clinic in 2H2019.
BriaCell management also attended Biotech Showcase 2019, an important investor conference that took place January 7-9 at the Hilton Union Square in San Francisco, California.
For more information, visit the company’s website at www.BriaCell.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
